Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Seeking Alpha • Dec 10, 2025

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS), multiple real world studies on the burden of depression and anti-seizure medication (ASM) titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 in Atlanta, Georgia.

GlobeNewsWire • Dec 5, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Dec 4, 2025

Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real world study data on the impact of depression and burden of titration in epilepsy. The webinar will also include an update on the company's progress preparing for commercialization of azetukalner.

GlobeNewsWire • Dec 3, 2025

Polarean shares jump 12% after Philips clears its Xenon lung-scan tech

Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) stock popped 12% to 0.14p on Monday after the company cleared a major technical hurdle in its bid to get Xenon-based lung scans into more hospitals. Philips has signed off on Polarean's XENOVIEW 3T chest coil, confirming it plays nicely with the Dutch giant's next wave of 3-tesla MRI scanners.

Proactive Investors • Dec 1, 2025

Polarean enters Asia with first Xenon MRI deal in Taiwan

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has secured its first foothold in Asia after National Taiwan University Hospital agreed to install one of the company's Xenon MRI research systems. The deal has been arranged through Philips, Polarean's long-standing strategic partner, and supported by Sumtage, the company's newly appointed distributor in Taiwan.

Proactive Investors • Nov 25, 2025

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company's Na V 1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice.

GlobeNewsWire • Nov 25, 2025

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ConferenceThursday, November 13, 2025 at 3:20 PM ET Webcast link here Jefferies Global Healthcare Conference in London onWednesday, November 19, 2025 at 11:30 AM GMT/6:30 AM ET Webcast link here Details about company presentations, webcasts, and other events can be found on the Investors section of Xenon's website.

GlobeNewsWire • Nov 6, 2025

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Johoon Kim - RBC Capital Markets, Research Division Charles Moore - Robert W. Baird & Co. Incorporated, Research Division Dina Ramadane - BofA Securities, Research Division Joseph Thome - TD Cowen, Research Division Brian Balchin - Jefferies LLC, Research Division Presentation Operator Good day, everyone, and thank you for standing by.

Seeking Alpha • Nov 4, 2025